Optimizing graft weight prediction in living donor liver transplantation: a machine learning approach integrating pathologic, radiological and biological factors
{"title":"Optimizing graft weight prediction in living donor liver transplantation: a machine learning approach integrating pathologic, radiological and biological factors","authors":"Shih-Min Yin, Po-Chun Chuang, Yu-Hung Lin, Itsuko Chih-Yi Chen, Yu-Fan Cheng, Shu-Mei Guo, Ting-Ting Liu, Chao-Long Chen, Jenn-Jier James Lien, Hsin-You Ou","doi":"10.1016/j.hpb.2026.04.457","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Graft weight (GW) prediction is essential in living donor liver transplantation (LDLT) to mitigate the risks associated with small-for-size grafts. This study aimed to develop and validate a machine learning (ML)-based model integrating clinical, biochemical, radiological, and histopathological features to enhance GW prediction accuracy.</div></div><div><h3>Materials and methods</h3><div>This study included 1001 LDLT donors between 2014 and 2023. Preoperative clinical data, graft volume (GV), radiological and histological steatosis grading were analysed. Multiple models were developed using an 80% training and 20% test split. Model performance was assessed using mean absolute error (MAE), root mean square error (RMSE), and mean absolute percentage error (MAPE) and compared with conventional GW prediction methods.</div></div><div><h3>Results</h3><div>The ML model demonstrated superior performance, with an MAE of 48.51 g, an RMSE of 65.12 g, and a MAPE of 8.49%. Compared with traditional methods, the ML approach significantly reduced prediction errors ≥15% (10.94% vs. 37.31% for conventional models, p < 0.001). Feature analysis highlighted GV, donor anthropometrics, lipid profiles, and CT attenuation values as key predictors, while hepatic steatosis had minimal impact.</div></div><div><h3>Conclusions</h3><div>ML-based GW prediction outperformed conventional methods by incorporating radiological and biochemical parameters, achieving greater accuracy and reducing clinically significant errors.</div></div>","PeriodicalId":13229,"journal":{"name":"Hpb","volume":"28 8","pages":"Pages 1076-1085"},"PeriodicalIF":3.3000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hpb","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1365182X26006027","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Graft weight (GW) prediction is essential in living donor liver transplantation (LDLT) to mitigate the risks associated with small-for-size grafts. This study aimed to develop and validate a machine learning (ML)-based model integrating clinical, biochemical, radiological, and histopathological features to enhance GW prediction accuracy.
Materials and methods
This study included 1001 LDLT donors between 2014 and 2023. Preoperative clinical data, graft volume (GV), radiological and histological steatosis grading were analysed. Multiple models were developed using an 80% training and 20% test split. Model performance was assessed using mean absolute error (MAE), root mean square error (RMSE), and mean absolute percentage error (MAPE) and compared with conventional GW prediction methods.
Results
The ML model demonstrated superior performance, with an MAE of 48.51 g, an RMSE of 65.12 g, and a MAPE of 8.49%. Compared with traditional methods, the ML approach significantly reduced prediction errors ≥15% (10.94% vs. 37.31% for conventional models, p < 0.001). Feature analysis highlighted GV, donor anthropometrics, lipid profiles, and CT attenuation values as key predictors, while hepatic steatosis had minimal impact.
Conclusions
ML-based GW prediction outperformed conventional methods by incorporating radiological and biochemical parameters, achieving greater accuracy and reducing clinically significant errors.
期刊介绍:
HPB is an international forum for clinical, scientific and educational communication.
Twelve issues a year bring the reader leading articles, expert reviews, original articles, images, editorials, and reader correspondence encompassing all aspects of benign and malignant hepatobiliary disease and its management. HPB features relevant aspects of clinical and translational research and practice.
Specific areas of interest include HPB diseases encountered globally by clinical practitioners in this specialist field of gastrointestinal surgery. The journal addresses the challenges faced in the management of cancer involving the liver, biliary system and pancreas. While surgical oncology represents a large part of HPB practice, submission of manuscripts relating to liver and pancreas transplantation, the treatment of benign conditions such as acute and chronic pancreatitis, and those relating to hepatobiliary infection and inflammation are also welcomed. There will be a focus on developing a multidisciplinary approach to diagnosis and treatment with endoscopic and laparoscopic approaches, radiological interventions and surgical techniques being strongly represented. HPB welcomes submission of manuscripts in all these areas and in scientific focused research that has clear clinical relevance to HPB surgical practice.
HPB aims to help its readers - surgeons, physicians, radiologists and basic scientists - to develop their knowledge and practice. HPB will be of interest to specialists involved in the management of hepatobiliary and pancreatic disease however will also inform those working in related fields.
Abstracted and Indexed in:
MEDLINE®
EMBASE
PubMed
Science Citation Index Expanded
Academic Search (EBSCO)
HPB is owned by the International Hepato-Pancreato-Biliary Association (IHPBA) and is also the official Journal of the American Hepato-Pancreato-Biliary Association (AHPBA), the Asian-Pacific Hepato Pancreatic Biliary Association (A-PHPBA) and the European-African Hepato-Pancreatic Biliary Association (E-AHPBA).